Therapeutic Potential of Stem Cells in Neurodegenerative Diseases

65

[56] R. Sims, S. J. van der Lee, A. C. Naj, et al., “Rare coding variants in

plcg2, abi3, and trem2 implicate microglial-mediated innate immunity

in alzheimer’s disease,” Nature Genetics, vol. 49, pp. 1373–1384, 9 2017.

[57] M. Honda, I. Minami, N. Tooi, et al., “The modeling of alzheimer’s

disease by the overexpression of mutant presenilin 1 in human embry-

onic stem cells,” Biochemical and Biophysical Research Communica-

tions, vol. 469, pp. 587–592, 1 2016.

[58] B. Foveau, A. S. Correia, S. S. Hébert, et al., “Stem cell-derived neu-

rons as cellular models of sporadic alzheimer’s disease,” Journal of

Alzheimer’s Disease, vol. 67, pp. 893–910, 2 2019.

[59] D. Y. Kim, S. H. Choi, J. S. Lee, et al., “Feasibility and effi-

cacy of intra-arterial administration of embryonic stem cell derived-

mesenchymal stem cells in animal model of alzheimer’s disease,” Journal

of Alzheimer’s Disease, vol. 76, pp. 1281–1296, 8 2020.

[60] Y. Shi, P. Kirwan, J. Smith, et al., “A human stem cell model of early

alzheimer’s disease pathology in down syndrome,” Science Translational

Medicine, vol. 4, 3 2012.

[61] T. Ubina, M. Magallanes, S. Srivastava, et al., “A human embryonic

stem cell model of aβ-dependent chronic progressive neurodegenera-

tion,” Frontiers in Neuroscience, vol. 13, 9 2019.

[62] W. Yue, Y. Li, T. Zhang, et al., “Esc-derived basal forebrain cholinergic

neurons ameliorate the cognitive symptoms associated with alzheimer’s

disease in mouse models,” Stem Cell Reports, vol. 5, pp. 776–790, 11

2015.

[63] A. McTague, G. Rossignoli, A. Ferrini, et al., “Genome editing in ipsc-

based neural systems: From disease models to future therapeutic strate-

gies,” Frontiers in Genome Editing, vol. 3, 3 2021.

[64] J. F. Arboleda-Velasquez, F. Lopera, M. O’Hare, et al., “Resistance to

autosomal dominant alzheimer’s disease in an apoe3 christchurch ho-

mozygote: a case report,” Nature Medicine, vol. 25, pp. 1680–1683, 11

2019.

[65] Y. L. Guen, M. E. Belloy, B. Grenier-Boley, et al., “Association of rare

<i>apoe</i> missense variants v236e and r251g with risk of alzheimer

disease,” JAMA Neurology, vol. 79, p. 652, 7 2022.

[66] C.-C. Liu, T. Kanekiyo, H. Xu, et al., “Apolipoprotein e and alzheimer

disease: risk, mechanisms and therapy,” Nature Reviews Neurology,

vol. 9, pp. 106–118, 2 2013.